Initiation of any new chronic therapy (e.g., ibuprofen, aerosolized rhDNase, hypertonic saline, azithromycin, tobramycin inhalation solution, aztreonam inhalation solution, ivacaftor) within 8 weeks prior to enrolment

introduction of vitamins or proton pump inhibitors within 8 weeks prior to enrolment

use of new investigational therapy within 4 weeks

current smoker; use of oral corticosteroids

Initiation of treatment or change in regimen for allergic bronchopulmonary aspergillosis or nontuberculous mycobacteria within 8 weeks.

liver enzymes \> 3 times the upper limit

pregnancy

FEV1 \< 50% of predicted.

Significant cardiovascular disease defined as abnormal EKG, known or suspected coronary artery disease or congestive heart failure.

Significant renal disease (Creatinine Clearance \< 30%).

Severe malnutrition (BMI \<18kg/m2)

Evaluation Of The Pan-microbiome and Host Immune Response in CF

What this study is about